Open AccessEfficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature
Author(s) -
Laura Loretan,
Linda Moskovszky,
Michael Kurrer,
G. U. Exner,
Andreas Trojan
Publication year - 2018
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000493370
Subject(s) - palbociclib , medicine , letrozole , liposarcoma , cyclin dependent kinase 4 , breast cancer , oncology , cancer research , cyclin dependent kinase , retinoblastoma , estrogen receptor , cancer , metastatic breast cancer , tamoxifen , cell cycle , pathology , sarcoma , cyclin dependent kinase 2 , biology , biochemistry , gene
Background: The cyclin D/cyclin-dependent kinase (CDK)4/6 inhibitor of the CDK4 (INK4)/retinoblastoma (Rb) pathway plays a crucial role in cell cycle progression. Selective CDK4/6 inhibitors specifically target a variety of tumors, with the main focus on hormone receptor(HR)-positive and human epidermal growth factor receptor 2(HER2)-negative breast cancer (BC). Case Report: We report on the efficacy of neoadjuvant palbociclib and letrozole application in a patient suffering from invasive estrogen receptor (ER)+/HER2- BC and concurrent well-differentiated and dedifferentiated liposarcoma (WD-DDLPS) of the thigh. Clinical and histological workup upon surgery revealed significant regressive changes in both the liposarcoma and the BC. The 24-month follow-up shows no signs of disease. Conclusion: CDK4/6 inhibitors exhibit a high therapeutic potential, although reliable prognostic markers need to be identified.